KLK3 and pachyonychia congenita: Among those patients with CA versus those without CA, there was a longer median follow-up [46.37 months vs 37.27 months], a higher pre-RP prostate specific antigen (PSA) score [8.10 ng/mL vs. 7.00 ng/mL], a higher Gleason score (52% versus 27%), and they were more likely to have T3a or higher stage PC (76% versus 53%) (120).